相关实验视频
Updated: Jul 15, 2025

08:02
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
Published on: January 22, 2020
5.5K
针对炎症性肠道疾病的疫苗治疗
Human vaccines & immunotherapeutics
|September 29, 2023
概括
治疗性疫苗为炎症性肠病 (IBD) 管理提供了一个有前途的替代方案,与目前的治疗方法相比,可能会提高疗效并减少副作用.
科学领域:
- 免疫学和胃肠道学
- 针对自身免疫性疾病的新型治疗策略.
背景情况:
- 目前的炎症性肠病 (IBD) 治疗方法,如乌斯特基努马布 (Ustekinumab),因弗利克西马布 (Infliximab) 和维多利祖马布 (Vedolizumab),在反应率和不良反应方面存在局限性.
- 需要更安全,更有效的IBD管理策略至关重要.
研究的目的:
- 审查有关IBD治疗疫苗的现有文献.
- 为研究人员提供关于IBD疫苗应用和前景的全面了解.
- 刺激用于IBD治疗的创新疫苗开发.
主要方法:
- 批判性地检查有关IBD治疗疫苗的当前科学文献.
- 分析与疫苗开发相关的免疫学研究进展.
- 评估疫苗的有效性,安全性和潜在的医疗负担减轻.
主要成果:
- 治疗性疫苗的目的是利用免疫系统产生用于IBD治疗的特定抗体.
- 疫苗提供了潜在的更有利的方法,由于提高了有效性和安全性.
- 有潜力减轻与IBD管理相关的财务和医疗负担.
结论:
- 治疗性疫苗代表了IBD管理的一个有希望的前沿.
- 需要进一步的研究和开发,以优化IBD的疫苗策略.
- 基于疫苗的疗法可以为IBD患者提供可持续和有效的长期解决方案.
更多相关视频
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
145
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
145
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
164
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
164
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
348
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
348
Drugs for Treatment of Ulcerative Colitis in IBD
164
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
164

